Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to $56.1 million.

  • 4D Molecular Therapeutics' Shares Outstanding (Weighted Average) rose 102.94% to $56.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.1 million, marking a year-over-year increase of 102.94%. This contributed to the annual value of $53.9 million for FY2024, which is 3785.75% up from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Shares Outstanding (Weighted Average) is $56.1 million, which was up 102.94% from $55.9 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $56.1 million for Q3 2025, and its period low was $26.7 million during Q1 2021.
  • For the 5-year period, 4D Molecular Therapeutics' Shares Outstanding (Weighted Average) averaged around $40.6 million, with its median value being $38.3 million (2023).
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first surged by 41986.29% in 2021, then skyrocketed by 102.94% in 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $27.7 million in 2021, then grew by 16.66% to $32.4 million in 2022, then increased by 20.95% to $39.1 million in 2023, then soared by 37.86% to $53.9 million in 2024, then grew by 4.05% to $56.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $56.1 million for Q3 2025, versus $55.9 million for Q2 2025 and $55.7 million for Q1 2025.